The relationship between high-sensitivity C-reactive protein and ApoB, ApoB/ApoA1 ratio in general population of China

Endocrine

Volumn 42, Issue 1, 2012, Pages 132-138

  Xu, Wanhua ^a,b   Li, Rong ^a   Zhang, Suhua ^a   Gong, Lilin ^a   Wang, Zhihong ^a   Ren, Wei ^a   Xia, Chenxi ^a   Li, Qifu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b THE FIRST PEOPLE S HOSPITAL OF FOSHAN   (China)

Author keywords

Apolipoprotein B; High sensitivity C reactive protein; Inflammation; Obesity; Waist circumference

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVITY C REACTIVE PROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CHINA; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84865044315     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9599-x     Document Type: Article

References (21)

1. S.S. Bassuk, N. Rifai, P.M. Ridker, High-sensitivity C-reactive protein: clinical importance. Curr. Probl. Cardiol. 29, 439-493 (2004)
2. P.M. Ridker, N. Rifai, L. Rose, J.E. Burning, N.R. Cook, Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347, 1557-1565 (2002)
3. F. Haverkate, S.G. Thompson, S.D. Pyke, J.R. Gallimore, M.B. Pepys, Production of C-reactive protein and risk of coronary in stable and unstable angina. European concerted action on thrombosis and disabilities angina pectoris study group. Lancet 349, 462-466 (1997)
4. M. Faraj, L. Messier, J.P. Bastard, A. Tardif, A. Godbout, D. Prud'homme, R. Rabasa-Lhoret, Apolipoprotein B: a predictor of inflammatory status in postmenopausal overweight and obese women. Diabetologia 49, 1637-1646 (2006)
5. J. Fan, T. Watanabe, Inflammatory reactions in the pathogenesis of atherosclerosis. J. Atheroscler. Thromb. 10, 63-71 (2003)
6. J. Sierra-Johnson, R.M. Fisher, A. Romero-Corral, V.K. Somers, F. Lopez-Jinmenez, J. Ohrvik, G. Walldius, M.L. Hellenius, A. Hamsten, Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur. Heart J. 30, 710-717 (2009)
7. Joint committee for developing chinese guidelines on prevention and treatment of dyslipidemia in adults, Chinese guidelines on prevention and treatment of dyslipidemia in adults. Chin. J. Cardiol. 35, 390-419 (2007). (in Chinese)
8. A.R. Sharret, C.M. Ballantyne, S.A. Coady, G. Heiss, P.D. Sorlie, D. Catellier, W. Patsch, Artheroscleosis risk in communities study group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins A-I and B, and HDL density subfractions: the atherosclerosis risk in communities (ARIC) study. Circulation 104, 1108-1113 (2001)
9. W.E. Boden, High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the veterans affairs high-density lipoprotein intervention trial. Am. J. Cardiol. 86, 19L-22L (2000)
10. G.W. Cockerill, K.A. Ryw, J.R. Gamble, M.A. Vadas, P.J. Barter, High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 15, 1987-1994 (1995)
11. N. Hyka, J.M. Dayer, C. Modoux, T. Kohno, C.K. Edwards 3rd, P. Roux-Lombard, D. Burger, Apolipoprotein A-I inhibits the production of interleukin-1 beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97, 2381-2389 (2000)
12. C.C. Hedrick, S.R. Thorpe, M.X. Fu, C.M. Harper, J. Yoo, S.M. Kim, H. Wong, A.L. Perers, Glycation impairs high-density lipoprotein function. Diabetologia 43, 312-320 (2000)
13. L. Perségol, B. Vergès, P. Gambert, L. Duvillard, Inability of HDL from abdominally obese subjects to counteract the inhibitory effect of oxidized LDL on vasorelaxation. J. Lipid Res. 48, 1396-1401 (2007)
14. T. Pischon, C.J. Girman, F.M. Sacks, N. Rifai, M.J. Stampfer, E.B. Rimm, Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112, 3375-3383 (2005)
15. K.L. Chien, H.C. Hsu, T.C. Su, M.F. Chen, Y.T. Lee, F.B. Hu, Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese. J. Lipid Res. 48, 2499-2505 (2007)
16. A.E. Hak, C.D. Stehouwer, M.L. Bots, K.H. Polderman, C.G. Schalkwijk, I.C. Westendorp, A. Hofman, J.C. Witteman, Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler. Thromb. Vasc. Biol. 19, 1986-1991 (1999)
17. I. Lemieux, A. Pascot, D. Prud'homme, N. Almėras, P. Bogaty, A. Nadeau, J. Bergeron, J.P. Desprės, Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler. Thromb. Vasc. Biol. 21, 961-967 (2001)
18. Y. Mugabo, L. Li, G. Renier, The connection between C-reactive protein (CRP) and diabetic vasculopay. Focus on preclinical findings. Curr. Diabetes Rev. 6, 27-34 (2010)
19. K. Brochu-gaudrea, C. Rehfeldt, R. Blouin, V. Bordignon, B.D. Murphy, M.F. Palin, Adiponectin action from head to toe. Endocrine 37, 11-32 (2010)
20. J.B. Li, A. Asakawa, K.C. Cheng, Y. Li, H. Chaolu, M. Tsai, A. Inui, Biological effects of obestatin. Endocrine 39, 205-211 (2011)
21. I. Castan-Lsurell, C. Dray, C. Arranė, T. Duparc, C. Knauf, P. Valet, Apelin, diabetes, and obesity. Endocrine 40, 1-9 (2011)